


1 A standard curve (The Amplification plot by SARS-CoV-2 virus replicate cycle) was provided by the  
 2 Shanghai Jienuo Company.



3  
 4 **Supplement Fig.1 The Amplification plot by SARS-CoV-2 virus replicate cycle (provided by**  
 5 **Shanghai Jienuo Company).**

8 **Supplement Table 1. Frequency and positive ratio in different sample site**

	# Tests	# Positive (% tests)	% Total
<b>Nasopharyngeal swab</b>	6,959	2,894 (41.59)	93.99%
<b>Blood</b>	144	21 (14.58)	1.94%
<b>BALF</b>	213	120 (56.34)	2.88%
<b>Saliva</b>	47	14 (29.79)	0.63%
<b>Eye discharge</b>	38	6 (15.79)	0.51%
<b>CSF</b>	2	0 (0.00)	0.03%
<b>Anal</b>	1	1 (100.00)	0.01%
<b>Total</b>	7,404	3,056	

9  
 10  
 11  
 12  
 13

14

**Supplement Table 2.** Impact of SARS-CoV-2 viral shedding on outcomes

	Non-adjusted	P value	Model I	P value	Model II	P value
<b>Outcome</b>						
<b>ICU Length</b>	0.52(0.90-0.96)	0.02	0.49 (0.42-0.94)	0.03	0.48 (-0.01-0.97)	0.05
<b>Hospital length</b>	0.15(-0.01,0.32)	0.07	0.11 (-0.05-0.26)	0.18	0.11 (-0.05-0.26)	0.18
<b>Death</b>	1.07(0.98, 1.17)	0.15	0.06 (-0.04-0.16)	0.23	0.06 (-0.04-0.16)	0.23

15

Data was presented as HR (95%CI) with P-value for death and coefficient (95%CI) P-value for ICU length and Hospital Length. Model I, adjusted for age and sex; Model II, adjusted for age, sex, and BMI.

16


17

18

19

20

21



22

23

*Fig.2 Box plot of Ct values at the time of admission for COVID-19 patients by specimen type.*

24